# Lexeo Therapeutics (LXEO) — Analyst Forecast

LXEO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lxeo/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 9 | 0 | 0 | 9 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 23, 2026 | Leerink Partners | Maintained | Outperform | $15.00 |
| Jun 25, 2026 | JP Morgan | Maintained | Overweight | $9.00 |
| May 11, 2026 | Chardan Capital | Maintained | Buy | $17.00 |
| Jan 13, 2026 | HC Wainwright & Co. | Maintained | Buy | $10.00 |
| Jan 13, 2026 | Chardan Capital | Maintained | Buy | $17.00 |
| Dec 18, 2025 | Raymond James | Initiated Coverage | Strong Buy | $25.00 |
| Dec 11, 2025 | Chardan Capital | Maintained | Buy | $17.00 |
| Dec 1, 2025 | Cantor Fitzgerald | Initiated Coverage | Overweight | $19.00 |
| Nov 20, 2025 | Cantor Fitzgerald | Initiated Coverage | Overweight | $19.00 |
| Nov 5, 2025 | Chardan Capital | Maintained | Buy | $17.00 |
| Oct 21, 2025 | HC Wainwright & Co. | Maintained | Buy | $13.00 |
| Oct 15, 2025 | Guggenheim | Initiated Coverage | Buy | $30.00 |
| Oct 7, 2025 | Leerink Partners | Maintained | Outperform | $20.00 |
| Oct 7, 2025 | Chardan Capital | Maintained | Buy | $17.00 |
| Oct 7, 2025 | HC Wainwright & Co. | Maintained | Buy | $15.00 |
| Aug 15, 2025 | HC Wainwright & Co. | Maintained | Buy | $9.00 |
| Aug 15, 2025 | Chardan Capital | Maintained | Buy | $15.00 |
| Jul 31, 2025 | Oppenheimer | Initiated Coverage | Outperform | $20.00 |
| May 30, 2025 | JP Morgan | Maintained | Overweight | $10.00 |
| May 16, 2025 | HC Wainwright & Co. | Maintained | Buy | $15.00 |

## Frequently Asked Questions

### Is LXEO a buy, sell, or hold?

Analysts covering Lexeo Therapeutics currently average a Buy rating: 9 buy, 0 hold and 0 sell, from 9 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on LXEO?

On Sep 23, 2026, Leerink Partners maintained Lexeo Therapeutics at Outperform with a price target of $15.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).